Specimen handling in the research context carries the same risks present in a clinical setting (specimen transposition and contamination), plus the added risk of fraudulent activity related to data representation and/or specimen acquisition. These types of complications are typically impossible to detect other than through DNA testing. DNA Specimen Provenance Assignment (DSPA) testing for clinical trials ensures the integrity of study results so informed conclusions can be made based on the most accurate results possible. From an economic perspective, incorporating this added measure of security can prevent significant financial losses from invalid study conclusions.
To learn more about incorporating Strand’s